Planta Med 2023; 89(01): 62-71
DOI: 10.1055/a-1906-1837
Biological and Pharmacological Activity
Original Papers

Pharmacological and Toxicological Study of Coumarinolignoids from Cleome viscosa in Small Animals for the Management of Rheumatoid Arthritis

Authors

  • Vineet Babu

    1   Bioprospection and Product Development Division, Council of Scientific and Industrial Research (CSIR) – Central Institute of Medicinal and Aromatic Plants (CIMAP), Lucknow, Uttar Pradesh, India.
  • Rupali Singh

    1   Bioprospection and Product Development Division, Council of Scientific and Industrial Research (CSIR) – Central Institute of Medicinal and Aromatic Plants (CIMAP), Lucknow, Uttar Pradesh, India.
  • Praveen K. Kashyap

    2   Phytochemistry Division, CSIR-CIMAP, Lucknow, Uttar Pradesh, India.
  • Kaveri R. Washimkar

    3   Department of Toxicology & Experimental Medicine, CSIR – Central Drug Research Institute (CDRI), Lucknow, Uttar Pradesh, India.
  • Madhav N. Mugale

    3   Department of Toxicology & Experimental Medicine, CSIR – Central Drug Research Institute (CDRI), Lucknow, Uttar Pradesh, India.
  • Sudeep Tandon

    2   Phytochemistry Division, CSIR-CIMAP, Lucknow, Uttar Pradesh, India.
  • Dnyaneshwar Umrao Bawankule

    1   Bioprospection and Product Development Division, Council of Scientific and Industrial Research (CSIR) – Central Institute of Medicinal and Aromatic Plants (CIMAP), Lucknow, Uttar Pradesh, India.
    4   Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh, India.

Gefördert durch: CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow HCP-007
Preview

Abstract

This study aims to explore the possible pharmacological potential of Cleome viscosa Linn (Cleomaceae), an annual weed, into therapeutic value-added products. In the present study, we have explored the pharmacological and toxicological profile of coumarinolignoids isolated from Cleome viscose for the management of rheumatoid arthritis and related complications in a small animal model. To avoid the biasness during experiments on animals, we have coded the isolated coumarinolignoids as CLIV-92 to perform the experimental pharmacological study. CLIV-92 was orally administrated (30,100, 300 mg/kg) to animal models of collagen-induced arthritis (CIA), carrageenan-induced acute inflammation, thermal and chemical-induced pain, and Brewerʼs yeast-induced pyrexia. Oral administration of CLIV-92 significantly decreases the arthritis index, arthritis score, and increases the limb withdrawal threshold in the CIA model in experimental rats. The anti-arthritis studies revealed that the anti-inflammatory effect of CLIV-92 was associated with inhibition of the production of inflammatory mediators like TNF-α, IL-6, IL-17A, MMP-1, MMP-9, Nitric oxide, and C-RP in CIA ratʼs serum, and also reduced the NFкB-p65 expression as evidence of immunohistochemistry in knee joint tissue of CIA rats, in a dose-dependent manner. Further individual experiments related to arthritis-related complications in experimental animals demonstrated the analgesic, anti-inflammatory, and antipyretic potential of CLIV-92 in a dose-dependent manner. Further, an in-vivo acute oral toxicity study concluded that CLIV-92 is safe in experimental animals up to 2,000 mg/kg dose. The results of this study suggested that the oral administration of CLIV-92 may be a therapeutic candidate for further investigation in the management of rheumatoid arthritis and related complications.



Publikationsverlauf

Eingereicht: 16. Dezember 2021

Angenommen nach Revision: 11. Juli 2022

Artikel online veröffentlicht:
27. September 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany